| __timestamp | Iovance Biotherapeutics, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 2917513 |
| Thursday, January 1, 2015 | 12390000 | 7878291 |
| Friday, January 1, 2016 | 25602000 | 8366794 |
| Sunday, January 1, 2017 | 21262000 | 6610381 |
| Monday, January 1, 2018 | 28430000 | 6556000 |
| Tuesday, January 1, 2019 | 40849000 | 6930000 |
| Wednesday, January 1, 2020 | 60210000 | 8758000 |
| Friday, January 1, 2021 | 83664000 | 10806000 |
| Saturday, January 1, 2022 | 104097000 | 9844000 |
| Sunday, January 1, 2023 | 106916000 | 13481000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Iovance Biotherapeutics, Inc. and Soleno Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Iovance's SG&A expenses surged by over 1,000%, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Soleno's expenses grew by approximately 360%, indicating a more conservative approach. Despite Iovance's higher absolute costs, their strategic investments may position them for long-term growth. Meanwhile, Soleno's steady expense management suggests a focus on sustainable operations. This comparison highlights the diverse strategies within the biotech sector, where balancing cost management with growth ambitions is key.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Soleno Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for GSK plc and Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Soleno Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?